Kewalramani Reshma
SEC CIK 1735944 · EDGAR
BoughtSold
Most active insiders at VRTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | LEIDEN JEFFREY M | Executive COB, Dir | — | $60.94M |
| 2 | Sachdev Amit | EVP Chief Patient, Ext Af Off | — | $28.38M |
| 3 | Kewalramani Reshma | CEO, Pres, Dir | — | $19.74M |
| 4 | Bozic Carmen | EVP, CMO | — | $11.31M |
| 5 | WAGNER CHARLES F JR | EVP, CO, FO | — | $10.78M |
| 6 | Tatsis Ourania | EVP, Chief Reg, Quality Off | — | $6.51M |
| 7 | McKechnie Duncan | EVP, Chief Commercial Off | — | $5.66M |
| 8 | Biller Jonathan | EVP, CLO | — | $4.08M |
| 9 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | — | $3.60M |
| 10 | Bunnage Mark E. | EVP, CSO | — | $3.00M |
Transactions 45
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-03-03 | 2026-02-27 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | S - Sale | $493.47 | -40.0K | 106.0K | -27% | -$19.74M |
| 2026-02-26 | 2026-02-24 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | F - Tax | $485.11 | -4,981 | 138.3K | -3% | -$2.42M | |
| 2026-02-19 | 2026-02-17 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | A - Grant | $0.00 | +16.3K | 149.8K | +12% | $0 | |
| 2026-02-19 | 2026-02-17 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | F - Tax | $483.75 | -6,554 | 143.3K | -4% | -$3.17M | |
| 2026-02-18 | 2026-02-13 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | F - Tax | $487.76 | -13.0K | 133.5K | -9% | -$6.36M | |
| 2026-02-12 | 2026-02-10 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | F - Tax | $468.41 | -8,297 | 146.5K | -5% | -$3.89M | |
| M | 2026-01-26 | 2026-01-22 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | A - Grant | $0.00 | +38.9K | 154.8K | +34% | $0 |
| M | 2025-08-07 | 2025-08-06 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | P - Purchase | $389.58 | +10.0K | 116.0K | +9% | +$3.90M |
| 2025-02-28 | 2025-02-26 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | F - Tax | $479.61 | -14.1K | 105.9K | -12% | -$6.75M | |
| 2025-02-26 | 2025-02-24 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | F - Tax | $483.28 | -9,386 | 120.0K | -7% | -$4.54M | |
| 2025-02-19 | 2025-02-14 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | F - Tax | $463.46 | -6,553 | 129.4K | -5% | -$3.04M | |
| 2025-02-14 | 2025-02-12 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | A - Grant | $0.00 | +19.0K | 135.9K | +16% | $0 | |
| 2025-02-12 | 2025-02-10 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | F - Tax | $467.98 | -8,300 | 116.9K | -7% | -$3.88M | |
| M | 2025-02-06 | 2025-02-04 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | A - Grant | $0.00 | +49.4K | 125.2K | +65% | $0 |
| 2024-11-12 | 2024-11-08 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | S - Sale | $515.00 | -15.2K | 75.8K | -17% | -$7.83M | |
| 2024-08-01 | 2024-07-30 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | S - Sale | $505.00 | -15.2K | 91.0K | -14% | -$7.68M | |
| 2024-07-24 | 2024-07-22 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | S - Sale | $497.00 | -15.2K | 106.2K | -13% | -$7.56M | |
| D | 2024-06-14 | 2024-06-12 | DNA | Ginkgo Bioworks Holdings, Inc. | Kewalramani Reshma | Dir | M - OptEx | — | +105.3K | 186.0K | +130% | — |
| D | 2024-05-29 | 2024-05-24 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | S - Sale+OE | $457.00 | -1,565 | 121.4K | -1% | -$715.2K |
| D | 2024-05-29 | 2024-05-24 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | M - OptEx | $187.53 | +1,565 | 122.9K | +1% | +$293.5K |
| 2024-05-22 | 2024-05-20 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | S - Sale | $447.00 | -15.2K | 121.4K | -11% | -$6.80M | |
| 2024-02-27 | 2024-02-23 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | F - Tax | $431.79 | -9,386 | 136.5K | -6% | -$4.05M | |
| M | 2024-02-21 | 2024-02-16+ | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | F - Tax | $422.54 | -16.4K | 145.9K | -10% | -$6.92M |
| 2024-02-13 | 2024-02-09 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | F - Tax | $422.74 | -8,255 | 162.3K | -5% | -$3.49M | |
| M | 2024-02-08 | 2024-02-06+ | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | A - Grant | $0.00 | +61.8K | 123.2K | +101% | $0 |
| DM | 2023-12-19 | 2023-12-15 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | M - OptEx | $181.83 | +17.1K | 111.8K | +18% | +$3.12M |
| D | 2023-12-19 | 2023-12-15 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | S - Sale+OE | $407.00 | -17.1K | 108.7K | -14% | -$6.97M |
| 2023-12-15 | 2023-12-13 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | S - Sale | $397.00 | -5,098 | 108.7K | -4% | -$2.02M | |
| 2023-11-15 | 2023-11-13 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | S - Sale | $377.00 | -5,097 | 113.8K | -4% | -$1.92M | |
| 2023-07-18 | 2023-07-17 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | S - Sale | $355.00 | -7,828 | 118.9K | -6% | -$2.78M | |
| M | 2023-05-01 | 2023-04-27 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | S - Sale | $339.08 | -3,317 | 126.7K | -3% | -$1.12M |
| 2023-02-28 | 2023-02-24 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | F - Tax | $289.12 | -9,386 | 130.0K | -7% | -$2.71M | |
| 2023-02-22 | 2023-02-17 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | F - Tax | $292.85 | -9,359 | 139.4K | -6% | -$2.74M | |
| M | 2023-02-14 | 2023-02-10+ | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | F - Tax | $296.84 | -9,362 | 154.7K | -6% | -$2.78M |
| M | 2023-02-03 | 2023-02-01 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | A - Grant | $0.00 | +68.5K | 102.0K | +204% | $0 |
| 2023-01-27 | 2023-01-25 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | S - Sale | $315.05 | -10.0K | 89.6K | -10% | -$3.15M | |
| D | 2022-11-10 | 2022-09-30 | DNA | Ginkgo Bioworks Holdings, Inc. | Kewalramani Reshma | Dir | M - OptEx | — | +9,818 | 80.7K | +14% | — |
| 2022-08-17 | 2022-08-15 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | S - Sale | $305.06 | -11.7K | 99.6K | -11% | -$3.57M | |
| 2022-06-28 | 2022-06-24 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | S - Sale | $291.30 | -11.7K | 111.2K | -10% | -$3.41M | |
| D | 2022-06-13 | 2022-06-10 | DNA | Ginkgo Bioworks Holdings, Inc. | Kewalramani Reshma | Dir | A - Grant | $0.00 | +70.9K | 70.9K | New | $0 |
| 2022-02-28 | 2022-02-24 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | F - Tax | $227.86 | -7,246 | 122.8K | -6% | -$1.65M | |
| 2022-02-22 | 2022-02-17 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | F - Tax | $232.51 | -8,584 | 130.1K | -6% | -$2.00M | |
| 2022-02-14 | 2022-02-10 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | F - Tax | $237.74 | -3,031 | 138.7K | -2% | -$720.6K | |
| M | 2022-02-03 | 2022-02-01 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | A - Grant | $0.00 | +67.9K | 112.6K | +152% | $0 |
| M | 2021-08-23 | 2021-08-19 | VRTX | Vertex Pharmaceuticals | Kewalramani Reshma | CEO, Pres, Dir | P - Purchase | $195.65 | +10.0K | 73.8K | +16% | +$1.96M |
Purchase Sale Sale after option exercise All abbreviations